Millennium Management’s Inozyme Pharma INZY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-481,799
| Closed | -$1.93M | – | 6234 |
|
|
2025
Q2 | $1.93M | Sell |
481,799
-762,923
| -61% | -$1.89M | ﹤0.01% | 3913 |
|
|
2025
Q1 | $1.13M | Sell |
1,244,722
-637,552
| -34% | -$884K | ﹤0.01% | 4255 |
|
|
2024
Q4 | $5.21M | Buy |
1,882,274
+137,821
| +8% | +$524K | ﹤0.01% | 2785 |
|
|
2024
Q3 | $9.12M | Sell |
1,744,453
-43,494
| -2% | -$226K | ﹤0.01% | 2259 |
|
|
2024
Q2 | $7.97M | Buy |
1,787,947
+1,084,341
| +154% | +$5.26M | ﹤0.01% | 2299 |
|
|
2024
Q1 | $5.39M | Sell |
703,606
-207,859
| -23% | -$1.14M | ﹤0.01% | 2790 |
|
|
2023
Q4 | $3.88M | Sell |
911,465
-415,406
| -31% | -$1.48M | ﹤0.01% | 3008 |
|
|
2023
Q3 | $5.57M | Sell |
1,326,871
-879,287
| -40% | -$4.47M | ﹤0.01% | 2600 |
|
|
2023
Q2 | $12.3M | Buy |
2,206,158
+515,083
| +30% | +$3.04M | 0.01% | 1815 |
|
|
2023
Q1 | $9.69M | Buy |
1,691,075
+1,393,139
| +468% | +$3.68M | 0.01% | 1987 |
|
|
2022
Q4 | $313K | Buy |
297,936
+127,752
| +75% | +$223K | ﹤0.01% | 5060 |
|
|
2022
Q3 | $456K | Sell |
170,184
-2,908
| -2% | -$10.5K | ﹤0.01% | 5038 |
|
|
2022
Q2 | $826K | Buy |
+173,092
| New | +$753K | ﹤0.01% | 4549 |
|
|
2022
Q1 | – | Sell |
-19,952
| Closed | -$136K | – | 7171 |
|
|
2021
Q4 | $136K | Buy |
19,952
+8,888
| +80% | +$76.8K | ﹤0.01% | 6121 |
|
|
2021
Q3 | $128K | Sell |
11,064
-50,249
| -82% | -$784K | ﹤0.01% | 6325 |
|
|
2021
Q2 | $1.04M | Sell |
61,313
-87,892
| -59% | -$1.53M | ﹤0.01% | 4620 |
|
|
2021
Q1 | $2.95M | Buy |
+149,205
| New | +$3.29M | ﹤0.01% | 3153 |
|
|
2020
Q4 | – | Sell |
-40,164
| Closed | -$1.06K | – | 5385 |
|
|
2020
Q3 | $1.06K | Buy |
+40,164
| New | +$998K | ﹤0.01% | 3093 |
|
Millennium Management's INZY Position: Q3 2025 in Review
Millennium Management sold out of Inozyme Pharma (INZY) in Q3 2025, closing a stake of 481,799 shares — an estimated $1.93M sold.
Millennium Management first reported a position in INZY in Q3 2020 and held it in 18 quarters. The position peaked at $12.3M in Q2 2023. 0 funds tracked by Wall St. Rank hold INZY as of Q3 2025.
- Millennium Management reported no remaining Inozyme Pharma position as of Q3 2025 after selling out during the quarter.
- Millennium Management sold 481,799 Inozyme Pharma shares in Q3 2025, an estimated $1.93M.
- Millennium Management first reported a position in Inozyme Pharma in Q3 2020 and held it in 18 quarters.
- Millennium Management's Inozyme Pharma position peaked at $12.3M in Q2 2023.
- 0 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2025.
Based on Millennium Management's 13F filing for Q3 2025, filed 14 Nov 2025.